HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q1 2023 13F Holders as of 31 Mar 2023

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
123,010,439
Share change
-4,584,555
Total reported value
$4,696,403,643
Put/Call ratio
39%
Price per share
$38.19
Number of holders
377
Value change
-$295,863,866
Number of buys
181
Number of sells
222

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q1 2023

As of 31 Mar 2023, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 377 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 123,010,439 shares. The largest 10 holders included BlackRock Inc., VANGUARD GROUP INC, Artisan Partners Limited Partnership, STATE STREET CORP, SNYDER CAPITAL MANAGEMENT L P, JPMORGAN CHASE & CO, Invesco Ltd., MACQUARIE GROUP LTD, GEODE CAPITAL MANAGEMENT, LLC, and GW&K Investment Management, LLC. This page lists 380 institutional shareholders reporting positions in this security for the Q1 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.